Symbiotec Subsidiary Signs U.S. Commercialization Deal for Injectable Products
Symbiotec Pharmalab Ltd 路 Others (Uncategorized) 路 01 Oct 2026, 1:39 am
Symbiotec Subsidiary Signs U.S. Commercialization Deal for Injectable Products Symbiotec Pharmalab鈥檚 wholly owned subsidiary, Knovea Pharmaceutical, has signed a definitive agreement with a leading global pharmaceutical company on 30th Sep'26. The partner gains exclusive rights to commercialize and distribute two Dual Chamber Vial (DCV) injectable products in the U.S., targeting an addressable market estimated at ~$288 million. Knovea will manage development, regulatory filings, manufacturing, and supply. In return, Knovea will receive development, regulatory, and commercial milestone payments, alongside ongoing post-launch profit-sharing.
Original exchange filing (PDF)
More announcements from Symbiotec Pharmalab Ltd
- Intimation regarding change in Corporate Identification Number (CIN) and Listing Status of the Company. 路 17 Nov 2026
- Transcript of the Earnings conference call for the Analysts and Investors for the Quarter and Half year ended 路 12 Nov 2026
- Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time .... 路 12 Nov 2026
- Pursuant to Part A of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audio recording of Conference Call for Analysts and Investors held on November .... 路 06 Nov 2026
- Symbiotec Signs 10 Year take or Pay Agreement to Manufacture Fermentation based alternative protein for EU Innovator 路 06 Nov 2026
- The Monitoring Agency report issued by the CARE Edge Ratings, Monitoring Agency, appointed by the Company for the utilisation and application of funds raised through the IPO of the Company .... 路 06 Nov 2026
- The Investor release being issued by the company, for the quarter and half year ended September 30, 2026 路 06 Nov 2026
- Pursuant to regulations 30 of the SEBI Listing Regulations, Investor Presentation on the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026. 路 06 Nov 2026
